These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 11803072)

  • 1. The cost-effectiveness of varicella vaccination in Canada.
    Brisson M; Edmunds WJ
    Vaccine; 2002 Jan; 20(7-8):1113-25. PubMed ID: 11803072
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The cost-effectiveness of varicella and combined varicella and herpes zoster vaccination programmes in the United Kingdom.
    van Hoek AJ; Melegaro A; Gay N; Bilcke J; Edmunds WJ
    Vaccine; 2012 Feb; 30(6):1225-34. PubMed ID: 22119592
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distribution of Health Effects and Cost-effectiveness of Varicella Vaccination are Shaped by the Impact on Herpes Zoster.
    van Lier A; Lugnér A; Opstelten W; Jochemsen P; Wallinga J; Schellevis F; Sanders E; de Melker H; van Boven M
    EBioMedicine; 2015 Oct; 2(10):1494-9. PubMed ID: 26629544
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Varicella vaccination in England and Wales: cost-utility analysis.
    Brisson M; Edmunds WJ
    Arch Dis Child; 2003 Oct; 88(10):862-9. PubMed ID: 14500303
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of varicella and herpes zoster vaccination in Sweden: An economic evaluation using a dynamic transmission model.
    Wolff E; Widgren K; Scalia Tomba G; Roth A; Lep T; Andersson S
    PLoS One; 2021; 16(5):e0251644. PubMed ID: 33984060
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modeling the impact of one- and two-dose varicella vaccination on the epidemiology of varicella and zoster.
    Brisson M; Melkonyan G; Drolet M; De Serres G; Thibeault R; De Wals P
    Vaccine; 2010 Apr; 28(19):3385-97. PubMed ID: 20199763
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Childhood varicella-zoster virus vaccination in Belgium: cost-effective only in the long run or without exogenous boosting?
    Bilcke J; van Hoek AJ; Beutels P
    Hum Vaccin Immunother; 2013 Apr; 9(4):812-22. PubMed ID: 23321955
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The epidemiologic and economic impact of varicella and herpes zoster vaccination in South Korea: A mathematical modelling study.
    Kim S; Choi JK; Suh J; Park SH; Lee J
    Vaccine; 2024 Jul; 42(19):4046-4055. PubMed ID: 38762358
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Varicella vaccination in Italy : an economic evaluation of different scenarios.
    Coudeville L; Brunot A; Giaquinto C; Lucioni C; Dervaux B
    Pharmacoeconomics; 2004; 22(13):839-55. PubMed ID: 15329030
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of routine varicella vaccination using the measles, mumps, rubella and varicella vaccine in France: an economic analysis based on a dynamic transmission model for varicella and herpes zoster.
    Littlewood KJ; Ouwens MJ; Sauboin C; Tehard B; Alain S; Denis F
    Clin Ther; 2015 Apr; 37(4):830-841.e7. PubMed ID: 25721380
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Modelling the impact of vaccination on the epidemiology of varicella zoster virus].
    Bonmarin I; Santa-Olalla P; Lévy-Bruhl D
    Rev Epidemiol Sante Publique; 2008 Oct; 56(5):323-31. PubMed ID: 18951741
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An economic evaluation and incremental analysis of the cost effectiveness of three universal childhood varicella vaccination strategies for Ireland.
    Ahern S; Browne J; Murphy A; Teljeur C; Ryan M
    Vaccine; 2024 May; 42(14):3321-3332. PubMed ID: 38609807
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epidemiology of varicella zoster virus infection in Canada and the United Kingdom.
    Brisson M; Edmunds WJ; Law B; Gay NJ; Walld R; Brownell M; Roos LL; De Serres G
    Epidemiol Infect; 2001 Oct; 127(2):305-14. PubMed ID: 11693508
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modelling the impact of a combined varicella and zoster vaccination programme on the epidemiology of varicella zoster virus in England.
    van Hoek AJ; Melegaro A; Zagheni E; Edmunds WJ; Gay N
    Vaccine; 2011 Mar; 29(13):2411-20. PubMed ID: 21277405
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The cost-effectiveness of varicella vaccine programs for Australia.
    Scuffham PA; Lowin AV; Burgess MA
    Vaccine; 1999 Oct; 18(5-6):407-15. PubMed ID: 10519929
    [TBL] [Abstract][Full Text] [Related]  

  • 16. What We Know Now: An Economic Evaluation of Chickenpox Vaccination and Dose Timing Using an Agent-Based Model.
    Rafferty ERS; McDonald W; Osgood ND; Doroshenko A; Farag M
    Value Health; 2021 Jan; 24(1):50-60. PubMed ID: 33431153
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of varicella vaccination programs: an update of the literature.
    Rozenbaum MH; van Hoek AJ; Vegter S; Postma MJ
    Expert Rev Vaccines; 2008 Aug; 7(6):753-82. PubMed ID: 18665775
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systematic review of models assessing the economic value of routine varicella and herpes zoster vaccination in high-income countries.
    Damm O; Ultsch B; Horn J; Mikolajczyk RT; Greiner W; Wichmann O
    BMC Public Health; 2015 Jun; 15():533. PubMed ID: 26041469
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The economic value of childhood varicella vaccination in France and Germany.
    Coudeville L; Brunot A; Szucs TD; Dervaux B
    Value Health; 2005; 8(3):209-22. PubMed ID: 15877593
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of Recombinant Zoster Vaccine (RZV) and Varicella Vaccine Live (VVL) against herpes zoster and post-herpetic neuralgia among adults aged 65 and over in Japan.
    Hoshi SL; Seposo X; Shono A; Okubo I; Kondo M
    Vaccine; 2019 Jun; 37(27):3588-3597. PubMed ID: 31153691
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.